Pharmapark LLC set up in 2001 develops and manufactures biopharmaceuticals derived using genetic engineering techniques. Its injection products, AltevirTM, GranogenTM and EpostimTM, are well known to Russian medical community. A lot of Russian producers of other dosage forms use the API of recombinant human interferon alfa-2b manufactured by Pharmapark.

The development strategy of Pharmapark is aimed at developing and manufacturing of biotechnologically derived original and biosimilar pharmaceuticals. The Group actively invests in new developments and is one of the leaders in the Russian biopharmaceutical market. 

Phone: +7 495 411 8594
Fax: +7 495 644 3797